This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kossaczka, Z.
Right arrow Articles by Szu, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kossaczka, Z.
Right arrow Articles by Szu, S. C.

 Previous Article  |  Next Article 

Infection and Immunity, November 1999, p. 5806-5810, Vol. 67, No. 11
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Safety and Immunogenicity of Vi Conjugate Vaccines for Typhoid Fever in Adults, Teenagers, and 2- to 4-Year-Old Children in Vietnam

Zuzana Kossaczka,1 Feng-Ying C. Lin,1 Vô Anh Ho,2 Nguyen Thi Thanh Thuy,3 Phan Van Bay,2 Tran Cong Thanh,3 Ha Ba Khiem,3 Dang Duc Trach,4 Arthur Karpas,1 Steven Hunt,1 Dolores A. Bryla,1 Rachel Schneerson,1 John B. Robbins,1 and Shousun C. Szu1,*

National Institutes of Health, Bethesda, Maryland 20892,1 Huu Nghi Hospital, Cao Lânh District, Dong Thap Province,2 Pasteur Institut, Ho Chi Minh City,3 and National Institute of Hygiene and Epidemiology, Hanoi,4 People's Republic of Vietnam

Received 7 June 1999/Returned for modification 13 July 1999/Accepted 13 August 1999

The capsular polysaccharide of Salmonella typhi, Vi, is an essential virulence factor and a protective vaccine for people older than 5 years. The safety and immunogenicity of two investigational Vi conjugate vaccines were evaluated in adults, 5- to 14-year-old children, and 2- to 4-year-old children in Vietnam. The conjugates were prepared with Pseudomonas aeruginosa recombinant exoprotein A (rEPA) as the carrier, using either N-succinimidyl-3-(2-pyridyldithio)-propionate (SPDP; Vi-rEPA1) or adipic acid dihydrazide (ADH; Vi-rEPA2) as linkers. None of the recipients experienced a temperature of >38.5°C or significant local reactions. One injection of Vi-rEPA2 into adults elicited a geometric mean (GM) increase in anti-Vi immunoglobulin G (IgG) from 9.62 enzyme-linked immunosorbent assay units/ml (EU) to 465 EU at 6 weeks; this level fell to 119 EU after 26 weeks. In the 5- to 14-year-old children, anti-Vi IgG levels at 6 weeks elicited by Vi-rEPA2, Vi-rEPA1, and Vi were 169, 22.8, and 18.9 EU, respectively (P = 0.0001 for Vi-rEPA1 and Vi with respect to Vi-rEPA2). At 26 weeks, the anti-Vi IgG levels for recipients of Vi-rEPA2, Vi-rEPA1, and Vi were 30.0, 10.8, and 13.4 EU, respectively (P < 0.001 for Vi-rEPA1 and Vi with respect to Vi-rEPA2); all were higher than the preinjection levels (P = 0.0001). Vi-rEPA2 also elicited the highest anti-Vi IgM and IgA levels of the three vaccines. In the 2- to 4-year-old children at 6 weeks following the first injection, Vi-rEPA2 elicited an anti-Vi IgG level of 69.9 EU compared to 28.9 EU for Vi-rEPA1 (P = 0.0001). Reinjection increased Vi antibody levels from 69.9 to 95.4 EU for Vi-rEPA2 and from 28.9 to 83.0 EU for Vi-rEPA1. At 26 weeks, anti-Vi IgG levels remained higher than those at preinjection (30.6 versus 0.18 for Vi-rEPA2 and 12.8 versus 0.33 for Vi-rEPA1; P = 0.0001 for both). Vi vaccine is recommended for individuals of 5 years of age or older. In the present study, the GM level of anti-Vi IgG elicited by two injections of Vi-rEPA2 in the 2- to 4-year-old children was higher than that elicited by Vi in the 5- to 14-year-old children (30.6 versus 13.4; P = 0.0001). The safety and immunogenicity of the Vi-rEPA2 conjugate warrant further investigation.

* Corresponding author. Mailing address: National Institutes of Health, Bethesda, MD 20892. Phone: (301) 496-4524. Fax: (301) 402-9108. E-mail: scszu{at}helix.nih.gov.

Infection and Immunity, November 1999, p. 5806-5810, Vol. 67, No. 11
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Kubler-Kielb, J., Majadly, F., Wu, Y., Narum, D. L., Guo, C., Miller, L. H., Shiloach, J., Robbins, J. B., Schneerson, R. (2007). Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Proc. Natl. Acad. Sci. USA 104: 293-298 [Abstract] [Full Text]  
  • Diemert, D. J. (2006). Prevention and Self-Treatment of Traveler's Diarrhea. Clin. Microbiol. Rev. 19: 583-594 [Abstract] [Full Text]  
  • Sharma, A., Qadri, A. (2004). Vi polysaccharide of Salmonella typhi targets the prohibitin family of molecules in intestinal epithelial cells and suppresses early inflammatory responses. Proc. Natl. Acad. Sci. USA 101: 17492-17497 [Abstract] [Full Text]  
  • Canh, D. G., Lin, F.-y., Thiem, V. D., Trach, D. D., Trong, N. D., Mao, N. D., Hunt, S., Schneerson, R., Robbins, J. B., Chu, C., Shiloach, J., Bryla, D. A., Bonnet, M.-C., Schulz, D., Szu, S. C. (2004). Effect of Dosage on Immunogenicity of a Vi Conjugate Vaccine Injected Twice into 2- to 5-Year-Old Vietnamese Children. Infect. Immun. 72: 6586-6588 [Abstract] [Full Text]  
  • Moore, S. E, Jalil, F., Ashraf, R., Chen Szu, S., Prentice, A. M, Hanson, L. A (2004). Birth weight predicts response to vaccination in adults born in an urban slum in Lahore, Pakistan. Am. J. Clin. Nutr. 80: 453-459 [Abstract] [Full Text]  
  • Chibber, S., Bhardwaj, S. B. (2004). Protection in a mouse peritonitis model mediated by iron-regulated outer-membrane protein of Salmonella typhi coupled to its Vi antigen. J Med Microbiol 53: 705-709 [Abstract] [Full Text]  
  • Rollenhagen, C., Sorensen, M., Rizos, K., Hurvitz, R., Bumann, D. (2004). Antigen selection based on expression levels during infection facilitates vaccine development for an intracellular pathogen. Proc. Natl. Acad. Sci. USA 101: 8739-8744 [Abstract] [Full Text]  
  • Lanh, M. N., Bay, P. V., Ho, V. A., Thanh, T. C., Lin, F. Y. C., Bryla, D. A., Chu, C., Schiloach, J., Robbins, J. B., Schneerson, R., Szu, S. C. (2003). Persistent Efficacy of Vi Conjugate Vaccine against Typhoid Fever in Young Children. NEJM 349: 1390-1391 [Full Text]  
  • Theilacker, C., Coleman, F. T., Mueschenborn, S., Llosa, N., Grout, M., Pier, G. B. (2003). Construction and Characterization of a Pseudomonas aeruginosa Mucoid Exopolysaccharide-Alginate Conjugate Vaccine. Infect. Immun. 71: 3875-3884 [Abstract] [Full Text]  
  • Mastroeni,, P., Menager, N. (2003). Development of acquired immunity to Salmonella. J Med Microbiol 52: 453-459 [Abstract] [Full Text]  
  • Lin, F. Y. C., Ho, V. A., Khiem, H. B., Trach, D. D., Bay, P. V., Thanh, T. C., Kossaczka, Z., Bryla, D. A., Shiloach, J., Robbins, J. B., Schneerson, R., Szu, S. C., Lanh, M. N., Hunt, S., Trinh, L., Kaufman, J. B. (2001). The Efficacy of a Salmonella typhi Vi Conjugate Vaccine in Two-to-Five-Year-Old Children. NEJM 344: 1263-1269 [Abstract] [Full Text]  
  • Shen, X., Lagergard, T., Yang, Y., Lindblad, M., Fredriksson, M., Holmgren, J. (2001). Group B Streptococcus Capsular Polysaccharide-Cholera Toxin B Subunit Conjugate Vaccines Prepared by Different Methods for Intranasal Immunization. Infect. Immun. 69: 297-306 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»